NCT04129528 - Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 8, 2019

Primary Completion Date

January 15, 2024

Study Completion Date

June 4, 2024

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG

CFZ533

First dose is administered via intravenous infusion, subsequent doses are administered subcutaneously.

OTHER

Placebo

Placebo for active drug

Trial Locations (12)

Novartis Investigative Site, Brussels

Novartis Investigative Site, Ljubljana

Novartis Investigative Site, Edegem

Novartis Investigative Site, Leuven

Novartis Investigative Site, Liège

Novartis Investigative Site, A Coruña

Novartis Investigative Site, Milan

Novartis Investigative Site, Málaga

Novartis Investigative Site, Florence

Novartis Investigative Site, Augsburg

Novartis Investigative Site, Esplugues de Llobregat

Novartis Investigative Site, Nottingham